抵抗抵抗:在慢性淋巴细胞白血病 (CLL) 中导航BTK突变
Alexandra Chirino1, Skye Montoya1, Anita Safronenka1
1Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL 33136, USA.
Genes
|December 23, 2023
概括
新布鲁顿的氨酸激酶 (BTK) 抑制剂对于治疗慢性淋巴细胞白血病 (CLL) 是至关重要的. 本综述检查了导致治疗耐药性的BTK突变,并讨论了克服这些突变的新疗法.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
- 分子生物学分子生物学
背景情况:
- 布鲁顿的氨酸激酶 (BTK) 在慢性淋巴细胞白血病 (CLL) 中对B细胞受体信号传递至关重要.
- BTK 抑制剂已经彻底改变了CLL的治疗方法,但耐药性和不良反应需要新一代药物.
- 新的BTK突变随着新一代抑制剂的使用增加而出现.
研究的目的:
- 审查CLL中已知的和新的BTK突变.
- 阐明这些突变所赋予的抗药性机制.
- 讨论当前和未来的治疗策略,以克服CLL中的BTK耐药性.
主要方法:
- 对BTK突变和CLL治疗研究的文献综述.
- 分析与各种BTK突变相关的抵抗机制.
- 讨论新兴疗法和治疗组合.
主要成果:
- 确定了已知的和新的BTK突变,这些突变有助于CLL治疗耐药性.
- 这些突变对BTK抑制剂产生抗性的详细机制.
- 突出了耐药性的不断演变,创造了一个未满足的临床需求.
结论:
- 在CLL管理中,BTK突变构成了重大挑战.
- 新的疗法和组合策略对于解决各种抗性机制至关重要.
- 需要进一步的研究来了解突变的起源,并为CLL患者开发持久的治疗方法.
更多相关视频
相关概念视频
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...


